Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FINE Trial: ctDNA-guided Adjuvant Chemotherapy in CRC
NCT05954078Phase 3Recruiting
- Sponsor
- Fudan University
- Start
- Aug 2023
- Primary completion
- Jun 2026
- Modality
- Nanoparticles, Monoclonal Antibodies, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab in colorectal cancer (CRC), sponsored by Fudan University. Started Aug 2023; status: recruiting.
02
Drugs
irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05954078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05954078.